Alshiyab Diala M, Al-Qarqaz Firas A, Alhaje Enas, Mayou Jihane A, Jaradat Saja, Asaad Ansam, Muhaidat Jihan M, Khader Yousef, Alsheyab Safa' M, Oweis Ashraf O, Khassawneh Basheer Y, Momany Suleiman M, Samrah Shaher M, Al-Ali Musa
Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Department of Public Health, Community Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Clin Cosmet Investig Dermatol. 2023 May 24;16:1331-1340. doi: 10.2147/CCID.S408958. eCollection 2023.
COVID-19 pandemic hit the entire world with severe health and economic consequences. Although the infection primarily affected the respiratory system, it was soon recognized that COVID-19 has a multi-systemic component with various manifestations including cutaneous involvement.
The main objective of this study is to assess the incidence and patterns of cutaneous manifestations among moderate-to-severe COVID-19 patients who required hospitalization and whether there was a prognostic indication for cutaneous involvement and the outcome in terms of recovery or death.
This is a cross-sectional observational study that included inpatients who were diagnosed with a moderate or severe COVID-19 infection. The demographic and clinical data of patients were assessed including age, sex, smoking, and comorbidities. All patients were examined clinically for the presence of skin manifestations. Patients were followed for the outcome of COVID-19 infection.
A total of 821 patients (356 females and 465 males) aged 4-95 years were included. More than half of patients (54.6%) aged >60 years. A total of 678 patients (82.6%) had at least one comorbid condition, mostly hypertension and diabetes mellitus. Sixty-two patients (7.55%) developed rashes; 5.24% cutaneous and 2.31% oral. The rashes were then grouped into five major types: group A, Exanthema: morbilliform, papulovesicular, varicella-like. Group B, Vascular: Chilblain-like lesions, purpuric/petechial, livedoid lesions. Group C, Reactive erythemas: Urticaria, Erythema multiforme. Group D, other skin rashes including flare-up of pre-existing disease, and O for oral involvement. Most patients (70%) developed rash after admission. The most frequent skin rashes were reactive erythema (23.3%), followed by vascular (20.9%), exanthema (16.3%), and other rashes with flare-ups of pre-existing diseases (39.5%). Smoking and loss of taste were associated with the appearance of various skin rashes. However, no prognostic implications were found between cutaneous manifestations and outcome.
COVID-19 infection may present with various skin manifestations including worsening of pre-existing skin diseases.
新冠疫情席卷全球,带来了严重的健康和经济后果。尽管该感染主要影响呼吸系统,但人们很快认识到新冠病毒具有多系统影响,有多种表现形式,包括皮肤受累。
本研究的主要目的是评估需要住院治疗的中重度新冠患者皮肤表现的发生率和类型,以及皮肤受累是否具有预后指示意义,以及康复或死亡方面的结局。
这是一项横断面观察性研究,纳入了被诊断为中重度新冠感染的住院患者。评估了患者的人口统计学和临床数据,包括年龄、性别、吸烟情况和合并症。对所有患者进行临床检查,以确定是否存在皮肤表现。对患者进行新冠感染结局的随访。
共纳入821例年龄在4至95岁之间的患者(356例女性和465例男性)。超过一半的患者(54.6%)年龄大于60岁。共有678例患者(82.6%)至少有一种合并症,主要是高血压和糖尿病。62例患者(7.55%)出现皮疹;5.24%为皮肤皮疹,2.31%为口腔皮疹。皮疹分为五大类:A组,疹:麻疹样、丘疹水疱样、水痘样。B组,血管性:冻疮样病变、紫癜/瘀点、类脂质性病变。C组,反应性红斑:荨麻疹、多形红斑。D组,其他皮疹,包括既往疾病复发,O组为口腔受累。大多数患者(70%)在入院后出现皮疹。最常见的皮肤皮疹是反应性红斑(23.3%),其次是血管性皮疹(20.9%)、疹(16.3%)和既往疾病复发的其他皮疹(39.5%)。吸烟和味觉丧失与各种皮肤皮疹的出现有关。然而,未发现皮肤表现与结局之间存在预后关联。
新冠病毒感染可能表现为各种皮肤表现,包括既往皮肤病的恶化。